Revision of section 3. 2. 5 of CPMP Note for guidance on Plasma- derived medicinal products
Points to consider on the clinical investigation of new medicinal products for treatment of acute coronary syndrome (ACS) without persistent ST- segment elevation Adoptée en février 2000